Camber is DSCSA Ready
Camber is fully prepared to meet the new Drug Supply Chain Security Act (DSCSA) requirements, ensuring enhanced traceability, verification, and safety across the pharmaceutical supply chain.
Learn more about how Camber prepared for DSCSA here
Recent articles
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
- Camber Welcomes Summer 2026 Intern Class
- Camber Launches 5 Generics in May






